On November 10, 2020 Lion TCR reported that it has presented two abstracts at the 2020 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 9-14 (Press release, Lion TCR, NOV 10, 2020, View Source [SID1234570478]). Each of these abstracts highlights the good safety profile and efficacy of LioCyx-M and the promising use of HBV-specific TCR-T therapy in HBV-related HCC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TCR-T immunotherapy involves the bioengineering reprogramming of the human body’s natural immune defenders, T cells, to enhance their cytolytic specificity function against tumour cells. Our clinical data presented in these abstracts supports the use of Lion TCR’s lead T-cell product, LioCyx-M is a promising TCR-T immunotherapy for primary hepatocellular carcinoma (HCC) and recurrence post liver transplantation.
Each of these abstracts highlights the good safety profile and efficacy of our lead product LioCyx-M, autologous T cells modified to express Hepatitis B virus (HBV)-specific TCR, as monotherapy in either unresectable HBV-associated hepatocellular carcinoma (HCC) or recurrent HCC post liver transplantation in two independent Phase I studies. These data demonstrate the promising use of HBV-specific TCR-T therapy in HBV-related HCC.
Details of the posters are as follows:
Title Use of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Advanced HBV-related Hepatocellular Carcinoma (HCC)
Abstract # 272
Co-corresponding authors Antonio Bertoletti and Fu-Sheng Wang
Presenting Author Fanping Meng
ClinicalTrials.gov number NCT03899415
Title Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation
Abstract # 273
Co-corresponding authors Antonio Bertoletti and Qi Zhang
Presenting Author Jintao Cheng
ClinicalTrials.gov number NCT02719782
The full abstracts are attached in this release and are also published online on 8 a.m. EST on Monday, Nov. 9, 2020 in Journal for ImmunoTherapy of Cancer (JITC).